2Turner P J.Extended-spectrum beta-lactamases[J].Clin Infect Dis,2005 ; 41 (suppl 4):s273-275.
3Zahar J R,Lortholary O,Martin C,et al.Addressing the challenge of extended-spectrum beta-lactamases[J].Curr Opin Inveatig Drugs,2009,10(2):172-180.
4Wagenlehner F M,Weidner W,Naber K G.Antibiotics in urology:new essentials[J].Urol Clin North Am,2008,35(1):69-79.
5Zhao L,Chen X,Zhu X,et al.Prevalence of virulence factors and antimicrobial resistance of uropathogenic Escherichia coli in Jiangsu province[J].Urology,2009,74(3):702-707.
6Arias C A,Murray B E.Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med,2009,360(5):439-443.
8Falagas M E,Bliziotis I A,Kasiakou S K,et al.Outcome of infections due to pandrug-resistant (PDR) gran-negative bacteria[J].BMC Infect Dis,2005,5(1):24.
9Cunha B A.New uses for older antibiotics:nitrofurantoin,amikacin,colistin,polymyxin B,doxycycline,and minocycline revisited[J].Med Clin North Am,2006,90(6):1089-1107.
10Burgess D S,Rapp R P.Bugs versus drugs:addressing the pharmacist's challenge[J].Am J Health Syst Pharm,2008,65(9 suppl 2):s4-s15.
